Video

Nizar Abdelfattah from UCLA David Geffen School of Medicine: Looking at Potential Impact of Medications on Macular Atrophy

Author(s):

Doctors treating patients with age-related macular degeneration face a wide range of complications including the potential dosage for anti-VEGF medications. One question is what role these drugs play in macular atrophy.

Doctors treating patients with age-related macular degeneration face a wide range of complications including the potential dosage for anti-VEGF medications. One question is what role these drugs play in macular atrophy.

Nizar Abdelfattah, MD, from the David Geffen School of Medicine at UCLA discussed the results of one such study during the annual meeting of the American Society of Retina Specialists in San Francisco. Abdelfattah said that while they were looking at whether the medication either caused atrophy or affected its progression they were unable to come up with any definitive answers to either question.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.